OpenResearchAlpha

Journal of Back and Musculoskeletal Rehabilitation · 12 Nov 2026

Effectiveness of weekly ergocalciferol 40,000 IU versus 80,000 IU in chronic myofascial pain syndrome and vitamin D deficiency: A randomized, single-blind, active-controlled trial

Chanakan Chuengmankhongh-index 0, Chanwit Phongamwongh-index 5

0
Citations
no database records one yet
0
Citations in 2026
so far
5
Leading author's h-index
Chanwit Phongamwong, in QAI's scholar index
28
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Background Vitamin D deficiency is prevalent in patients with chronic myofascial pain syndrome (MPS) and has been proposed as a potential medical precipitating factor. However, no clinical trials have compared different vitamin D supplementation doses in patients with chronic MPS and vitamin D deficiency. Objectives This study aimed to compare the effects of weekly ergocalciferol 40,000 IU (standard dose) and 80,000 IU (high dose) on serum 25(OH)D levels and clinically meaningful pain reduction. Methods In this randomized, single-blind, active-controlled trial, 70 patients were randomly assigned to receive high-dose (n = 35) or standard-dose (n = 35) ergocalciferol for 8 weeks. The primary outcome was the proportion achieving optimal serum 25(OH)D (≥30 ng/mL). Secondary outcomes included ≥30% pain reduction and symptomatic adverse effects. Multiple imputation was used to handle missing data. Results At week 8, mean serum 25(OH)D was higher in the high-dose group than in the standard-dose group (46.6 ng/mL; 95% CI, 40.6–52.7 vs. 34.4 ng/mL; 95% CI, 30.9–37.9). However, the high-dose regimen did not significantly increase the odds of achieving optimal serum 25(OH)D (aOR, 3.23; 95% CI, 0.77–13.42) or ≥30% pain reduction (aOR, 1.17; 95% CI, 0.33–4.10). Clinically meaningful pain reduction occurred in 75.8% and 66.7% of the high- and standard-dose groups, respectively. No symptomatic adverse effects were reported in either group. Conclusion Although the 80,000-IU weekly regimen resulted in higher serum 25(OH)D levels, it did not demonstrate a significant advantage over the 40,000-IU weekly regimen in achieving optimal vitamin D status or clinically meaningful pain reduction after 8 weeks.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Chanwit Phongamwong has the highest h-index among the authors (5).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (2)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (28)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 8 more references

A free account opens the rest of the citing papers and references on every paper’s page.